Wall Street brokerages expect that Orthofix International N.V. (NASDAQ:OFIX) will report $101.60 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Orthofix International N.V.’s earnings. The lowest sales estimate is $100.50 million and the highest is $102.70 million. Orthofix International N.V. reported sales of $98.50 million during the same quarter last year, which indicates a positive year over year growth rate of 3.1%. The business is expected to announce its next earnings report on Monday, October 30th.

On average, analysts expect that Orthofix International N.V. will report full year sales of $101.60 million for the current fiscal year, with estimates ranging from $423.60 million to $425.00 million. For the next financial year, analysts forecast that the business will report sales of $444.60 million per share, with estimates ranging from $440.70 million to $451.60 million. Zacks’ sales averages are an average based on a survey of research analysts that follow Orthofix International N.V..

Orthofix International N.V. (NASDAQ:OFIX) last announced its quarterly earnings results on Monday, August 7th. The medical device company reported $0.42 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.01. The business had revenue of $108.90 million during the quarter, compared to the consensus estimate of $102.94 million. Orthofix International N.V. had a net margin of 1.88% and a return on equity of 9.96%. The business’s revenue was up 4.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.41 EPS.

A number of equities analysts have weighed in on OFIX shares. TheStreet raised shares of Orthofix International N.V. from a “c+” rating to a “b-” rating in a research note on Tuesday, August 8th. BTIG Research initiated coverage on shares of Orthofix International N.V. in a research report on Wednesday, June 21st. They issued a “buy” rating and a $52.00 price objective for the company. Langenberg & Company reissued a “buy” rating and issued a $53.25 price objective on shares of Orthofix International N.V. in a research report on Wednesday, June 14th. Ladenburg Thalmann Financial Services initiated coverage on shares of Orthofix International N.V. in a research report on Wednesday, June 14th. They issued a “buy” rating and a $53.25 price objective for the company. Finally, BidaskClub lowered shares of Orthofix International N.V. from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Seven equities research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus price target of $52.75.

In other Orthofix International N.V. news, CFO Rice Doug sold 7,353 shares of the firm’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $49.46, for a total transaction of $363,679.38. Following the completion of the transaction, the chief financial officer now directly owns 44,743 shares of the company’s stock, valued at approximately $2,212,988.78. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Brad Mason sold 2,733 shares of the firm’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $48.10, for a total transaction of $131,457.30. Following the transaction, the chief executive officer now directly owns 188,053 shares of the company’s stock, valued at $9,045,349.30. The disclosure for this sale can be found here. Over the last three months, insiders have sold 23,406 shares of company stock valued at $1,138,531. 5.60% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the business. Pinebridge Investments L.P. grew its holdings in Orthofix International N.V. by 2.3% during the 2nd quarter. Pinebridge Investments L.P. now owns 2,378 shares of the medical device company’s stock worth $111,000 after acquiring an additional 53 shares in the last quarter. Mason Street Advisors LLC bought a new position in shares of Orthofix International N.V. in the 1st quarter worth about $159,000. State of Alaska Department of Revenue lifted its position in shares of Orthofix International N.V. by 79.3% in the 2nd quarter. State of Alaska Department of Revenue now owns 3,551 shares of the medical device company’s stock worth $165,000 after buying an additional 1,571 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Orthofix International N.V. in the 1st quarter worth about $175,000. Finally, BNP Paribas Arbitrage SA lifted its position in shares of Orthofix International N.V. by 68.9% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,656 shares of the medical device company’s stock worth $178,000 after buying an additional 1,900 shares during the last quarter. 94.40% of the stock is owned by institutional investors.

Shares of Orthofix International N.V. (OFIX) opened at 50.68 on Friday. The firm has a market cap of $920.86 million, a P/E ratio of 118.69 and a beta of 0.20. Orthofix International N.V. has a one year low of $32.51 and a one year high of $51.09. The stock’s 50 day moving average is $48.66 and its 200-day moving average is $44.16.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/08/101-60-million-in-sales-expected-for-orthofix-international-n-v-ofix-this-quarter.html.

Orthofix International N.V. Company Profile

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Get a free copy of the Zacks research report on Orthofix International N.V. (OFIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Orthofix International N.V. (NASDAQ:OFIX)

Receive News & Stock Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related stocks with our FREE daily email newsletter.